Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Author Correction: Laquinimod treatment in the R6/2 mouse model.

Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R.

Sci Rep. 2019 Mar 15;9(1):4960. doi: 10.1038/s41598-018-37926-4.

2.

Role of Aramchol in steatohepatitis and fibrosis in mice.

Iruarrizaga-Lejarreta M, Varela-Rey M, Fernández-Ramos D, Martínez-Arranz I, Delgado TC, Simon J, Juan VG, delaCruz-Villar L, Azkargorta M, Lavin JL, Mayo R, Van Liempd SM, Aurrekoetxea I, Buqué X, Cave DD, Peña A, Rodríguez-Cuesta J, Aransay AM, Elortza F, Falcón-Pérez JM, Aspichueta P, Hayardeny L, Noureddin M, Sanyal AJ, Alonso C, Anguita J, Martínez-Chantar ML, Lu SC, Mato JM.

Hepatol Commun. 2017 Nov;1(9):911-927. doi: 10.1002/hep4.1107. Epub 2017 Oct 4.

3.

Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.

Moore S, Khalaj AJ, Patel R, Yoon J, Ichwan D, Hayardeny L, Tiwari-Woodruff SK.

J Neurosci Res. 2018 Jan;96(1):172-173. doi: 10.1002/jnr.24137. No abstract available.

PMID:
29120092
4.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS.

Ziemssen T, Tumani H, Sehr T, Thomas K, Paul F, Richter N, Samara E, Spiegelstein O, Sorani E, Bar-Ilan O, Mimrod D, Hayardeny L.

J Neuroinflammation. 2017 Aug 31;14(1):172. doi: 10.1186/s12974-017-0945-z.

5.

Laquinimod treatment in the R6/2 mouse model.

Ellrichmann G, Blusch A, Fatoba O, Brunner J, Reick C, Hayardeny L, Hayden M, Sehr D, Winklhofer KF, Saft C, Gold R.

Sci Rep. 2017 Jul 10;7(1):4947. doi: 10.1038/s41598-017-04990-1. Erratum in: Sci Rep. 2019 Mar 15;9(1):4960.

6.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
7.

Laquinimod enhances central nervous system barrier functions.

Lühder F, Kebir H, Odoardi F, Litke T, Sonneck M, Alvarez JI, Winchenbach J, Eckert N, Hayardeny L, Sorani E, Lodygin D, Flügel A, Prat A.

Neurobiol Dis. 2017 Jun;102:60-69. doi: 10.1016/j.nbd.2017.02.002. Epub 2017 Feb 22.

PMID:
28235673
8.

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA.

Sci Rep. 2016 Aug 16;6:31652. doi: 10.1038/srep31652.

9.

Laquinimod prevents cuprizone-induced demyelination independent of Toll-like receptor signaling.

Kramann N, Menken L, Hayardeny L, Hanisch UK, Brück W.

Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(3):e233. doi: 10.1212/NXI.0000000000000233. eCollection 2016 Jun.

10.

Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research.

Grossman I, Knappertz V, Laifenfeld D, Ross C, Zeskind B, Kolitz S, Ladkani D, Hayardeny L, Loupe P, Laufer R, Hayden M.

Prog Neurobiol. 2017 May;152:114-130. doi: 10.1016/j.pneurobio.2016.02.001. Epub 2016 Mar 4. Review.

PMID:
26952809
11.

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.

Dobson L, Träger U, Farmer R, Hayardeny L, Loupe P, Hayden MR, Tabrizi SJ.

J Neurochem. 2016 Jun;137(5):782-94. doi: 10.1111/jnc.13553. Epub 2016 Apr 5.

12.

A New Targeted Model of Experimental Autoimmune Encephalomyelitis in the Common Marmoset.

Stassart RM, Helms G, Garea-Rodríguez E, Nessler S, Hayardeny L, Wegner C, Schlumbohm C, Fuchs E, Brück W.

Brain Pathol. 2016 Jul;26(4):452-64. doi: 10.1111/bpa.12292. Epub 2015 Sep 22.

PMID:
26207848
13.

Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.

Stasiolek M, Linker RA, Hayardeny L, Bar Ilan O, Gold R.

Immun Inflamm Dis. 2015 Jun;3(2):45-55. doi: 10.1002/iid3.42. Epub 2015 Mar 4.

14.

The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.

Zilkha-Falb R, Gurevich M, Hayardeny L, Achiron A.

J Neuroimmunol. 2015 Jun 15;283:11-6. doi: 10.1016/j.jneuroim.2015.04.007. Epub 2015 Apr 11.

PMID:
26004150
15.

Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.

Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, Schwartz R, Komlosh A, Hayardeny L, Ladkani D, Hayden MR, Zeskind B, Grossman I.

Sci Rep. 2015 May 22;5:10191. doi: 10.1038/srep10191.

16.

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.

Mishra MK, Wang J, Keough MB, Fan Y, Silva C, Sloka S, Hayardeny L, Brück W, Yong VW.

Ann Clin Transl Neurol. 2014 Jun;1(6):409-22. doi: 10.1002/acn3.67. Epub 2014 May 26.

17.

Immune surveillance of the central nervous system in multiple sclerosis--relevance for therapy and experimental models.

Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Deason K, Castro-Rojas C, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):9-17. doi: 10.1016/j.jneuroim.2014.08.622. Epub 2014 Aug 30. Review.

18.

Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.

Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O.

J Neuroimmunol. 2014 Nov 15;276(1-2):232-5. doi: 10.1016/j.jneuroim.2014.08.624. Epub 2014 Sep 2.

19.

In vitro assessment of the direct effect of laquinimod on basic functions of human neural stem cells and oligodendrocyte progenitor cells.

Kelland EE, Gilmore W, Hayardeny L, Weiner LP, Lund BT.

J Neurol Sci. 2014 Nov 15;346(1-2):66-74. doi: 10.1016/j.jns.2014.07.058. Epub 2014 Aug 4.

PMID:
25125045
20.

Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis.

Pitarokoili K, Ambrosius B, Schrewe L, Hayardeny L, Hayden M, Gold R.

J Neuroimmunol. 2014 Sep 15;274(1-2):38-45. doi: 10.1016/j.jneuroim.2014.06.012. Epub 2014 Jun 24.

PMID:
25005118
21.

Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.

Moore S, Khalaj AJ, Patel R, Yoon J, Ichwan D, Hayardeny L, Tiwari-Woodruff SK.

J Neurosci Res. 2014 Dec;92(12):1621-36. doi: 10.1002/jnr.23440. Epub 2014 Jul 3. Erratum in: J Neurosci Res. 2018 Jan;96(1):172-173.

22.

Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.

Moore S, Khalaj AJ, Yoon J, Patel R, Hannsun G, Yoo T, Sasidhar M, Martinez-Torres L, Hayardeny L, Tiwari-Woodruff SK.

Brain Behav. 2013 Nov;3(6):664-82. doi: 10.1002/brb3.174. Epub 2013 Sep 23.

23.

Assessment of changes in immune measures of multiple sclerosis patients treated with laquinimod.

Lund BT, Kelland EE, Hayardeny L, Barilan O, Gilmore W, Weiner LP.

J Neuroimmunol. 2013 Oct 15;263(1-2):108-15. doi: 10.1016/j.jneuroim.2013.07.008. Epub 2013 Aug 6.

PMID:
23920036
24.

Glatiramer acetate protects against inflammatory synaptopathy in experimental autoimmune encephalomyelitis.

Gentile A, Rossi S, Studer V, Motta C, De Chiara V, Musella A, Sepman H, Fresegna D, Musumeci G, Grasselli G, Haji N, Weiss S, Hayardeny L, Mandolesi G, Centonze D.

J Neuroimmune Pharmacol. 2013 Jun;8(3):651-63. doi: 10.1007/s11481-013-9436-x. Epub 2013 Jan 31.

PMID:
23370991
25.

Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.

Ruffini F, Rossi S, Bergamaschi A, Brambilla E, Finardi A, Motta C, Studer V, Barbieri F, De Chiara V, Hayardeny L, Comi G, Centonze D, Martino G.

Mult Scler. 2013 Jul;19(8):1084-94. doi: 10.1177/1352458512469698. Epub 2012 Dec 11.

PMID:
23232603
26.

Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis.

Toubi E, Nussbaum S, Staun-Ram E, Snir A, Melamed D, Hayardeny L, Miller A.

J Neuroimmunol. 2012 Oct 15;251(1-2):45-54. doi: 10.1016/j.jneuroim.2012.07.003. Epub 2012 Jul 28.

PMID:
22846497
27.

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.

Brück W, Pförtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, Hanisch UK, Regen T, van Rossum D, Brakelmann L, Hagemeier K, Kuhlmann T, Stadelmann C, John GR, Kramann N, Wegner C.

Acta Neuropathol. 2012 Sep;124(3):411-24. doi: 10.1007/s00401-012-1009-1. Epub 2012 Jul 6.

28.

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.

Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R.

J Neuroimmunol. 2012 Oct 15;251(1-2):14-24. doi: 10.1016/j.jneuroim.2012.06.005. Epub 2012 Jun 28.

PMID:
22749337
29.

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

Thöne J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R.

Am J Pathol. 2012 Jan;180(1):267-74. doi: 10.1016/j.ajpath.2011.09.037. Epub 2011 Dec 5.

PMID:
22152994
30.

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.

Wegner C, Stadelmann C, Pförtner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Brück W.

J Neuroimmunol. 2010 Oct 8;227(1-2):133-43. doi: 10.1016/j.jneuroim.2010.07.009. Epub 2010 Aug 3.

PMID:
20684995
31.

Glatiramer acetate-reactive T lymphocytes regulate oligodendrocyte progenitor cell number in vitro: role of IGF-2.

Zhang Y, Jalili F, Ouamara N, Zameer A, Cosentino G, Mayne M, Hayardeny L, Antel JP, Bar-Or A, John GR.

J Neuroimmunol. 2010 Oct 8;227(1-2):71-9. doi: 10.1016/j.jneuroim.2010.06.014. Epub 2010 Jul 15.

32.

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.

Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E, Ben-Asher E, Paperna T, Pe'er I, Lancet D, Beckmann JS, Miller A.

Pharmacogenet Genomics. 2007 Aug;17(8):657-66.

PMID:
17622942

Supplemental Content

Loading ...
Support Center